



● Akt inhibitors

Discovery	Cat.No.	Product Name	Information	Selectivity	Clinical Trial
2009	S1078	MK-2206 2HCl	Akt1 Akt2 Akt3 IC ₅₀ (nM) 8 12 65		Phase 2
2008	S1113	GSK690693	Akt1 Akt2 Akt3 Others IC ₅₀ (nM) 2 13 9 PKA, PrkX, PKC		Phase 1
2002	S1037	Perifosine (KRX-0401)	Akt IC ₅₀ (μM) 4.7		Phase 3
2011	S2808	GDC-0068	Akt1 Akt2 Akt3 IC ₅₀ (nM) 5 18 8		Phase 2
1993	S1117	Triciribine	Akt IC ₅₀ (nM) 130	Others HIV-1	Phase 1/2
2011	S2635	CCT128930	Akt2 IC ₅₀ (nM) 6	Others PKA, p70S6K	
2005	S2670	A-674563	Akt1 K _i (nM) 11	Others PKA, PKCδ, CDK2, ERK2, GSK-3β	
2010	S1558	AT7867	Akt1 Akt2 Akt3 IC ₅₀ (nM) 32 17 47	Others p70S6K, PKA	
2012	S8019	AZD5363	Akt1 Akt2 Akt3 IC ₅₀ (nM) 3 8 8	Others p70S6K/PKA, ROCK1/2	Phase 1/2
1991	S3056	Miltefosine	Miltefosine inhibits PI3K/Akt activity with ED ₅₀ of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.		Phase 4